WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406400
CAS#: 17374-26-4
Description: Tetrabromobenzotriazole, also known as TBB and NSC231634, is a potent protein kinase CK2 inhibitor, which induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells.
Hodoodo Cat#: H406400
Name: Tetrabromobenzotriazole
CAS#: 17374-26-4
Chemical Formula: C6HBr4N3
Exact Mass: 430.69
Molecular Weight: 434.708
Elemental Analysis: C, 16.58; H, 0.23; Br, 73.52; N, 9.67
Synonym: TBB, Tetrabromobenzotriazole, NSC 231634, NSC231634, NSC-231634
IUPAC/Chemical Name: 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
InChi Key: OMZYUVOATZSGJY-UHFFFAOYSA-N
InChi Code: InChI=1S/C6HBr4N3/c7-1-2(8)4(10)6-5(3(1)9)11-13-12-6/h(H,11,12,13)
SMILES Code: BrC1=C(NN=N2)C2=C(Br)C(Br)=C1Br
Appearance: White solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 434.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Gyenis L, Kuś A, Bretner M, Litchfield DW. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2. J Proteomics. 2013 Apr 9;81:70-9. doi: 10.1016/j.jprot.2012.09.017. Epub 2012 Sep 25. PubMed PMID: 23017496.
2: Orzechowska E, Kozłowska E, Staroń K, Trzcińska-Danielewicz J. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol Rep. 2012 Jan;27(1):281-5. doi: 10.3892/or.2011.1500. Epub 2011 Oct 12. PubMed PMID: 21993828.
3: Isaeva AR, Mitev VI. The protein kinase CK2 inhibitor TBB mediates up-regulation of MEK3/6 and p38δ activities, down-regulation of ERK1/2 activity and induction of G1/S arrest in normal human epidermal autocrine proliferating keratinocytes. J Dermatol Sci. 2011 Aug;63(2):124-6. doi: 10.1016/j.jdermsci.2011.04.005. Epub 2011 Apr 27. PubMed PMID: 21620683.
4: Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J. 2002 May 15;364(Pt 1):41-7. PubMed PMID: 11988074; PubMed Central PMCID: PMC1222543.
